CA2894466A1 - Uses and methods for the treatment of liver diseases or conditions - Google Patents

Uses and methods for the treatment of liver diseases or conditions Download PDF

Info

Publication number
CA2894466A1
CA2894466A1 CA2894466A CA2894466A CA2894466A1 CA 2894466 A1 CA2894466 A1 CA 2894466A1 CA 2894466 A CA2894466 A CA 2894466A CA 2894466 A CA2894466 A CA 2894466A CA 2894466 A1 CA2894466 A1 CA 2894466A1
Authority
CA
Canada
Prior art keywords
liver
diamidine
pentamidine
administered
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2894466A
Other languages
English (en)
French (fr)
Inventor
Patrick Colin
Pierre Falardeau
Francois Ravenelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VERLYX PHARMA Inc
Original Assignee
VERLYX PHARMA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VERLYX PHARMA Inc filed Critical VERLYX PHARMA Inc
Publication of CA2894466A1 publication Critical patent/CA2894466A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
CA2894466A 2012-12-21 2013-12-20 Uses and methods for the treatment of liver diseases or conditions Abandoned CA2894466A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745011P 2012-12-21 2012-12-21
US61/745,011 2012-12-21
PCT/CA2013/051003 WO2014094176A1 (en) 2012-12-21 2013-12-20 Uses and methods for the treatment of liver diseases or conditions

Publications (1)

Publication Number Publication Date
CA2894466A1 true CA2894466A1 (en) 2014-06-26

Family

ID=50977490

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2894466A Abandoned CA2894466A1 (en) 2012-12-21 2013-12-20 Uses and methods for the treatment of liver diseases or conditions

Country Status (12)

Country Link
US (2) US9375411B2 (cg-RX-API-DMAC7.html)
EP (1) EP2934501A4 (cg-RX-API-DMAC7.html)
JP (1) JP6370801B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150126595A (cg-RX-API-DMAC7.html)
CN (1) CN104968340A (cg-RX-API-DMAC7.html)
AU (1) AU2013362755B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015014836A2 (cg-RX-API-DMAC7.html)
CA (1) CA2894466A1 (cg-RX-API-DMAC7.html)
HK (1) HK1216721A1 (cg-RX-API-DMAC7.html)
MX (1) MX2015007945A (cg-RX-API-DMAC7.html)
RU (1) RU2015126505A (cg-RX-API-DMAC7.html)
WO (1) WO2014094176A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3073185A1 (en) * 2017-08-15 2019-02-21 Progenity, Inc. Treatment of inflammatory disease using ingestible device to release immune modulator
MA51151A (fr) 2017-11-16 2020-10-21 Montdorex Inc Inhibiteurs d'endo-exonucléase mono- et di-amidine et procédés d'inhibition de l'activité endo-exonucléase
CN110478340A (zh) * 2018-05-14 2019-11-22 复旦大学 喷他嘧啶羟乙基磺酸盐在制备肝癌药物方面的应用
JP2022544624A (ja) 2019-08-16 2022-10-19 アプライド モレキュラー トランスポート インコーポレイテッド 組成物、製剤およびインターロイキンの生成および精製

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA388674A (en) * 1940-05-14 The B. F. Goodrich Company Brake structure
GB1288376A (cg-RX-API-DMAC7.html) 1968-10-29 1972-09-06
DE2833135A1 (de) 1978-07-28 1980-02-07 Henkel Kgaa Verwendung von substituierten oligocarbamidinen als mikrobistatika sowie diese enthaltende antimikrobielle mittel
US5204113A (en) 1987-04-09 1993-04-20 Fisons Plc Pharmaceutical compositions containing pentamidine
US5084480A (en) 1987-11-06 1992-01-28 Fujisawa Usa, Inc. Pentamidine salts useful in the treatment of pneumocystis carinii pneumonia
US4853416A (en) 1988-04-25 1989-08-01 Fisons Corporation Solutions of pentamidine
US5162361A (en) * 1990-04-10 1992-11-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Method of treating diseases associated with elevated levels of interleukin 1
DE4321444A1 (de) 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
JPH08333324A (ja) 1995-06-08 1996-12-17 Terumo Corp ベンゼン誘導体およびそれを含有する医薬製剤
JP3540457B2 (ja) 1995-09-11 2004-07-07 テルモ株式会社 抗血栓性を賦与した医療用基材
JP3635238B2 (ja) 1998-11-10 2005-04-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖの複製を阻害するピリミジン類
US7884090B2 (en) 1999-03-17 2011-02-08 Ernest L. Bonner, Jr. Compositions and methods for the treatment of arthritis
US7115665B1 (en) 2000-11-16 2006-10-03 Onocozyme Pharma, Inc. Inhibitors of endo-exonuclease activity for treating cancer
US6569853B1 (en) 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US7416723B2 (en) 2001-09-07 2008-08-26 The Cleveland Clinic Foundation Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
US20040010045A1 (en) 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
WO2003092616A2 (en) * 2002-05-01 2003-11-13 The Cleveland Clinic Foundation Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
US20050054708A1 (en) 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
US7994225B2 (en) 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
EP1732527A2 (en) 2004-03-17 2006-12-20 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
WO2007001455A2 (en) 2004-11-12 2007-01-04 Mediquest Therapeutics, Inc. Hydrophobic polyamine amides as potent lipopolysaccharide sequestrants
TW200719903A (en) 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
US7199267B1 (en) 2005-10-21 2007-04-03 Mediquest Therapeutics, Inc. Recognition of oligiosaccaride molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases
WO2007100663A2 (en) 2006-02-22 2007-09-07 University Of Kansas Polyamines and their use as antibacterial and sensitizing agents
US20080226596A1 (en) 2006-06-19 2008-09-18 Taolin Yi Therapeutic compositions and methods useful in treating hepatitis
DE102008007381A1 (de) 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
DE102008007426A1 (de) 2008-02-01 2009-08-06 Rheinische Friedrich-Wilhelms-Universität Bonn Unbenetzbare Oberflächen
US8436049B2 (en) 2008-02-21 2013-05-07 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Uses of pentamidine and related compounds
EP2424516A4 (en) * 2009-05-01 2014-04-02 Oncozyme Pharma Inc PENTAMIDINE COMBINATIONS FOR THE TREATMENT OF CANCER
US20120277193A1 (en) 2009-09-21 2012-11-01 President And Fellows Of Harvard College Synergistic Combination Therapy
US20130244963A1 (en) 2010-09-30 2013-09-19 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
PL2550963T3 (pl) 2011-07-25 2017-08-31 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg Estry kwasu amidooksymokarboksylowego pentamidyny jako proleki i ich zastosowanie jako leki
EP2872390B1 (en) * 2012-07-11 2016-08-24 Waterbox Oy Apparatus for providing rotating movement

Also Published As

Publication number Publication date
US9827211B2 (en) 2017-11-28
CN104968340A (zh) 2015-10-07
AU2013362755A1 (en) 2015-07-02
US20150297540A1 (en) 2015-10-22
JP2016503035A (ja) 2016-02-01
AU2013362755B2 (en) 2018-09-13
US9375411B2 (en) 2016-06-28
JP6370801B2 (ja) 2018-08-08
HK1216721A1 (zh) 2016-12-02
KR20150126595A (ko) 2015-11-12
BR112015014836A2 (pt) 2017-07-11
MX2015007945A (es) 2016-02-16
EP2934501A1 (en) 2015-10-28
US20160287535A1 (en) 2016-10-06
RU2015126505A (ru) 2017-01-27
WO2014094176A1 (en) 2014-06-26
EP2934501A4 (en) 2016-06-01

Similar Documents

Publication Publication Date Title
JP6931004B2 (ja) ２−ブロモ−１−（３，３−ジニトロアゼチジン−１−イル）エタノンの静脈内投与のための組成物および方法
CN105338977B (zh) 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
AU2018357775B2 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
JP6557684B2 (ja) 線維性疾患の治療に用いられるｐｐａｒ化合物
JP4569106B2 (ja) 臓器線維化抑制剤
US12465598B2 (en) Methods of treating migraine
US9827211B2 (en) Uses and methods for the treatment of liver diseases or conditions
EP2793857B1 (en) Drug delivery technology
US20120108641A1 (en) Antitumor combination including ave8062 and sorafenib
CN117398372A (zh) Ostarine在抑制NLRP3炎症小体活化中的应用
TWI777059B (zh) 肌肉減少症之預防劑及治療劑
RU2485956C2 (ru) Новая композиция для лечения побочных эффектов противораковой терапии
WO2019242688A1 (zh) 3-羟基氨基苯甲酸与索拉非尼联合用药治疗肿瘤
JP2018529752A (ja) サンダルウッド油及び口腔粘膜炎に関連するその用途
EP4005556A1 (en) Pharmaceutical composition comprising udenafil
KR20210126515A (ko) 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
EP4556472A1 (en) Use of pyridone derivative
EP4640218A1 (en) Use of sultam compound in treating biliary tract cancer
CN112533604A (zh) 用于治疗癌症的组合疗法
JP6935930B2 (ja) 生薬成分を含む肺高血圧症の予防又は治療剤
JP2004231557A (ja) エピネフリン含有抗腫瘍剤
WO2025221288A1 (en) Treatment of diseases via administration of buntanetap and an antihypertensive agent
JP2018108969A (ja) リンパ浮腫の治療薬

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181126

FZDE Discontinued

Effective date: 20210831

FZDE Discontinued

Effective date: 20210831